← Back to patent-cliff list
HB-5
Tier C — Watch / tradeHB-5
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：基底鳞状细胞癌, 原位癌, Acne vulgaris, Actinic keratosis
Regional status
US
-
EU
-
China
Phase II
2026-03-02
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HB-5?
Approved indications include: 基底鳞状细胞癌, 原位癌, Acne vulgaris, Actinic keratosis.
When does the HB-5 patent expire?
No public expiry year is available for HB-5 yet; this page updates once verified.
How do I get a quote for HB-5 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29